Your session is about to expire
← Back to Search
Talazoparib + Belinostat for Metastatic Cancer
Study Summary
This trial is testing a new combination of drugs to treat metastatic breast, prostate, and ovarian cancers. They want to see if it is safe and what the best dose is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 & 2 trial • 40 Patients • NCT02116777Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a hysterectomy, oophorectomy, or tubal ligation, with documentation.I have cancer that has spread to my brain or surrounding membranes.I do not have uncontrolled high blood pressure or diabetes.My last radiation therapy was over 3 weeks ago.My condition has worsened recently.I have another cancer that is getting worse or needs treatment.I am fully active or can carry out light work.My organs and bone marrow are working well.My brain metastases have been treated and are stable for over 4 weeks.I am using two effective birth control methods if I can have children.I have not had periods for less than 2 years without surgical removal of my uterus and ovaries, and my hormone levels indicate I am postmenopausal.I haven't had a heart attack or severe heart issues in the last 6 months.I have another cancer type, but it won't affect this trial's treatment.I am over 45 and have not had a period in more than 2 years.I am not currently in a clinical trial that involves treatment.I am not using, and do not plan to use strong P-gp inhibitors soon.I have been treated with a histone deacetylase inhibitor.I do not have any uncontrolled serious health conditions.I am currently on medication for an infection.I can take pills without significant issues like severe nausea or problems absorbing medication.My heart's electrical cycle is longer than normal.I am not using, and do not plan to use, certain drugs that affect UGT1A1 during the study.My test shows I have two copies of the UGT1A1*28 gene variant.I am 21 days past my last chemotherapy and have recovered from its side effects, except for hair loss and nerve issues.I am not allergic to talazoparib, belinostat, or their inactive ingredients.
- Group 1: Talozoparib in combination with Belinostat
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what illnesses is Talazoparib most commonly administered?
"Talazoparib is approved to treat refractory peripheral t-cell lymphoma unspecified, malignant neoplasms, and relapsed peripheral t-cell lymphoma."
Is this examination currently open to new subjects?
"As per clinicaltrials.gov, this study is actively recruiting for participants and was initially posted on April 3rd 2021 before being modified on March 31st 2022."
Are there any risks associated with utilizing Talazoparib as a therapy?
"Based on the sparse evidence that exists, our team at Power gave Talazoparib a score of 1 to reflect its status as an early-phase trial."
Are there any additional experiments that have studied Talazoparib?
"At the moment, 65 clinical trials are being conducted with Talazoparib. Out of these studies, 3 have reached Phase 3. While primarily based in Boston Massachusetts, 2345 sites across America provide access to this medication."
How many participants are being included in this trial?
"Affirmative. Clinicaltrials.gov data indicates that this medical trial is currently accepting volunteers and was most recently modified on March 31st, 2022. 25 individuals are being sought from a singular site."
Share this study with friends
Copy Link
Messenger